A spokesperson said the trial has not raised any safety care for children, but also stood for Britain’s Medicines and Healthcare products Regulatory Agency, or MHRA, reviews are rare cases of people who suffer from blood clots while at the same time having low levels of blood platelets.
“All visits scheduled to attend the trial site parents and children so that they can contact if they have any questions,” the spokesperson said.
Where are the CNN, AstraZeneca queries referred to Oxford University.
At the MHRA, Dr. June Raine, MHRA, as told CNN on Tuesday was “aware of the University of Oxford in decision making has taken for the safety of dosing trial … MHRA review is still ongoing.”
“Participate in any clinical trial safety is our top priority, but there is also reported from this trial,” he added.
MHRA said in a statement it received 22 reports of cerebral venous sinus thrombosis (CVST), where the clotting forms in the sinuses that drain blood from the brain and eight other reports of thrombosis in a total of 15.8 million people, who have been given at least one dose of 21 March a vaccine.
The only way to tell how many people are expected at 15.8 million blood clots
The agency has already warned that the UK should continue administering the vaccine in all groups, arguing that such clotting and abroad are rare and that the benefits that greatly outweigh fears that similar assessment was made of the European finishing medicines Agency (EMA) and the World Health Organization (OMS).
Control and blood clots were reported in countries that have not received the vaccine, especially in Europe, where AstraZeneca vaccine is widely used. Some countries in the vaccine are choosing to suspend altogether, while others use limited to certain age groups.
Blood clots in general are so common that it is expected that a certain number of people will get them for various reasons at any given day of any given week. If someone is far from the vaccine, and he had a blood clot develops, it is not necessarily the cause of the clot in the middle of the shot.
After a month, he handed over the last of clotting is initial, AstraZeneca is quick to point out that the overall mushrooms, the man who fell into the general population who has not received in the lower parts of the shot.
An AstraZeneca spokesperson said in a statement to CNN last week, “the Company’s patient safety remains the top priority,” and pointed to authorities in the UK, and any recommendations for the EU to continue its use.
“What is good for the vaccine risk profile of the bishops reaffirmed a month update info on health,” the spokesperson said.
Carl Richard Allen Greene, CNN’s Dewan attention to this report.